New immune cell combo targets hard-to-treat lymphoma in early trial
NCT ID NCT05618925
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment shrinks tumors. Participants must have tried at least two prior chemotherapies and received rituximab before.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN'S LYMPHOMA REFRACTORY/RELAPSED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92663, United States
-
Texas Oncology
RECRUITINGTyler, Texas, 75702, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cells engineered to fight lymphoma enter human testing
- New combo therapy shows promise for tough lymphoma cases
- New study aims to crack the code of treatment resistance in lymphoma
- New injection shows promise for Hard-to-Treat cancers
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- Engineered killer cells take on Hard-to-Treat lymphoma